Stopped Trial for Bleeding Reduction With Abelacimab in AF
A phase 2 trial of the investigational factor severe bleeding in patients taking abelacimab versus those taking rivaroxaban. The announcement of the main results of the AZALEA-TIMI 71 trial was made by Anthos Therapeutics, the company developing abelacimab. “The AZALEA-TIMI 71 study is the largest and longest comparative study of a Factor XI inhibitor to … Read more